[{"orgOrder":0,"company":"LUCA Science","sponsor":"Axil Capital Partners","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"JAPAN","productType":"Undisclosed","year":"2020","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Discovery","graph3":"LUCA Science","amount2":0.01,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","amount2New":0.01,"dosageForm":"Oral","sponsorNew":"LUCA Science \/ Axil Capital Partners","highestDevelopmentStatusID":"2","companyTruncated":"LUCA Science \/ Axil Capital Partners"},{"orgOrder":0,"company":"LUCA Science","sponsor":"University of Oxford","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"JAPAN","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Preclinical","graph3":"LUCA Science","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"LUCA Science \/ University of Oxford","highestDevelopmentStatusID":"4","companyTruncated":"LUCA Science \/ University of Oxford"},{"orgOrder":0,"company":"LUCA Science","sponsor":"Fast Track Initiative","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"JAPAN","productType":"Undisclosed","year":"2022","type":"Series B Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Preclinical","graph3":"LUCA Science","amount2":0.029999999999999999,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0.029999999999999999,"dosageForm":"Undisclosed","sponsorNew":"LUCA Science \/ Fast Track Initiative","highestDevelopmentStatusID":"4","companyTruncated":"LUCA Science \/ Fast Track Initiative"},{"orgOrder":0,"company":"LUCA Science","sponsor":"Kyowa Kirin","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"JAPAN","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Discovery","graph3":"LUCA Science","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"LUCA Science \/ Kyowa Kirin","highestDevelopmentStatusID":"2","companyTruncated":"LUCA Science \/ Kyowa Kirin"}]

Find Clinical Drug Pipeline Developments & Deals by LUCA Science

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          ESCRS
                          Not Confirmed
                          ESCRS
                          Not Confirmed

                          Details : Proceeds from financing will also be used to establish a robust manufacturing system based on its proprietary Mitochondrial Isolation Technology platform, a novel method for intact, shelf-stable and highly functional isolated mitochondria as a biopharmac...

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Undisclosed

                          June 06, 2022

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                          Highest Development Status : Preclinical

                          Sponsor : Fast Track Initiative

                          Deal Size : $30.3 million

                          Deal Type : Series B Financing

                          blank

                          02

                          ESCRS
                          Not Confirmed
                          ESCRS
                          Not Confirmed

                          Details : LUCA Science will use its proprietary platform technology to manufacture, store and deliver innovative mitochondrial drugs to research and development of therapeutics for unmet medical needs in a wide range of diseases for which there have been no effect...

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Undisclosed

                          May 18, 2022

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Rare Diseases and Disorders

                          Highest Development Status : Discovery

                          Sponsor : Kyowa Kirin

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          03

                          ESCRS
                          Not Confirmed
                          ESCRS
                          Not Confirmed

                          Details : This collaboration was formed in order to realise this solution and seeks to address this by specifically delivering therapeutics to the placenta, combining unique technology developed at LUCA Science with extensive placental research experience at the U...

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Undisclosed

                          December 09, 2020

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                          Highest Development Status : Preclinical

                          Sponsor : University of Oxford

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          04

                          ESCRS
                          Not Confirmed
                          ESCRS
                          Not Confirmed

                          Details : LUCA Science is developing an innovative platform of highly functional mitochondrial using proprietary technologies. LUCA Science’s mitochondria can be stored and delivered as a biopharmaceutical agent.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Undisclosed

                          January 09, 2020

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Neurology

                          Highest Development Status : Discovery

                          Sponsor : Axil Capital Partners

                          Deal Size : $9.8 million

                          Deal Type : Series A Financing

                          blank